Will Revvity (NYSE:RVTY) Build on a 7.8% Gain After Raising Its 2026 Outlook?

Vinay Lochav

05 November 2026 12:48 AM AEDT

Will Revvity (NYSE:RVTY) Build on a 7.8% Gain After Raising Its 2026 Outlook?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revvity (NYSE:RVTY) gained 7.8% on November 3, 2026, after raising its full-year forecast alongside third-quarter results released that day.
Third-quarter Revenue was USD 728.9 million against USD 698.9 million, with pro forma organic growth of 7% and adjusted Earnings of USD 1.38 a share against USD 1.18.
Life Sciences revenue reached USD 379.6 million, with pro forma organic growth of 9%, while Diagnostics revenue was USD 349.3 million, with pro forma organic growth of 5%.
New 2026 pro forma adjusted earnings guidance is USD 5.40 to USD 5.45 a share on about USD 2.86 billion of revenue, with organic growth of about 5%.

What Revvity Reported

Revvity reported third-quarter 2026 results on November 3, 2026, for the quarter ended October 4. Reported revenue was USD 728.9 million, up from USD 698.9 million, and pro forma organic growth was 7%. Adjusted earnings from continuing operations were USD 1.38 a share against USD 1.18, while GAAP earnings were USD 0.56 against USD 0.41. Life Sciences revenue was USD 379.6 million, with an adjusted Operating Margin of 31.5%. Diagnostics revenue was USD 349.3 million, down from USD 356.1 million as reported, with an adjusted operating margin of 29.9%. Shares closed up 7.84%, according to published market data. Reported and pro forma figures differ because the pro forma basis puts revenue at USD 709.6 million and pro forma adjusted earnings at USD 1.37. That is the basis management uses for guidance and for comparison with the prior year.

What the Raised Outlook Says

Pro forma figures adjust for portfolio changes, and Revvity's guidance excludes its China IDX business. The company now expects 2026 pro forma revenue of about USD 2.86 billion, organic growth of about 5% and pro forma adjusted earnings of USD 5.40 to USD 5.45 a share. The release says guidance went up but does not state the prior range, so the size of the increase cannot be quantified here. The mix stands out: Life Sciences grew faster than Diagnostics, and Diagnostics reported lower revenue despite 5% organic growth, so currency and portfolio effects explain part of the gap. Investors must therefore weigh pro forma growth, which management stresses, against reported revenue, which rose about 4.3%, simple arithmetic on USD 728.9 million against USD 698.9 million.

Risks and Signals to Track

Revvity sells instruments and reagents to research labs, drug makers and diagnostic laboratories, so funding for academic research and Drug Development drives demand. Diagnostics growth of 5% organic is solid but slower than Life Sciences. Pro forma numbers can also hide restructuring effects, and the missing prior guidance range limits comparison. A 7.8% one-day rise raises expectations for the fourth quarter. Investors will watch Life Sciences organic growth, Diagnostics volumes, margins and any further portfolio changes, plus the next outlook update. The Diagnostics adjusted operating margin of 29.9% is a useful gauge of whether the mix is holding, as is the Life Sciences margin of 31.5%.

Where Things Stand

Revvity can build on a 7.8% jump only if fourth-quarter organic growth stays near the roughly 5% it now guides for the year and margins hold. The latest quarter showed 7% organic growth, higher adjusted earnings and a raised forecast, which explains the gain. The limits are slower Diagnostics growth and the missing prior guidance range. For Revvity (NYSE:RVTY), the next checkpoint is the fourth-quarter report. A one-day rally is not a forecast. Nothing here is Investment advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.